文献速递脑血管病

血糖控制对CYP2C19基因变异患者氯吡格雷疗效的影响

Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With CYP2C19 Genetic Variants.
PubMed 文献 · Stroke · 2017-03-13

基于CHANCE试验2933例携带GA水平和CYP2C19基因分型的短暂性脑缺血发作或小卒中患者,评估糖化白蛋白水平与CYP2C19功能缺失等位基因对抗血小板治疗疗效的交互作用。结果显示在GA≤15.5%的患者中,携带状态与抗血小板方案对卒中复发风险存在显著交互作用(P=0.03),仅在非携带者且低GA水平中,双联抗血小板治疗较阿司匹林单药显著降低卒中复发(3.5% vs 14.7%;HR 0.23;95%CI 0.10-0.49;P<0.001)。

要点

  • GA≤15.5%且CYP2C19非携带者,双抗较单抗显著降低卒中复发。
  • GA>15.5%时,CYP2C19状态与抗血小板方案无显著交互作用(P=0.48)。
  • 各组间出血无显著差异。

核心结论

  • 在小卒中或高危TIA患者中,氯吡格雷联合阿司匹林较阿司匹林单药仅在CYP2C19功能缺失等位基因非携带者且GA水平正常时降低卒中复发。

研究设计与样本

  • 基于CHANCE试验的二次分析,纳入2933例有GA水平和CYP2C19基因分型的患者,采用Cox比例风险模型评估交互作用。

主要发现

  • GA≤15.5%患者中,CYP2C19携带状态与抗血小板方案对卒中复发风险存在显著交互作用(P=0.03)。
  • GA>15.5%患者中,交互作用不显著(P=0.48)。
  • GA≤15.5%的非携带者中,双抗组卒中复发3.5%,单抗组14.7%(HR 0.23;95%CI 0.10-0.49;P<0.001)。
  • 联合血管事件或缺血性卒中分析结果相似。
  • 各组间出血无显著差异。

关键数值与推荐

  • GA阈值15.5%用于分层分析。
  • CYP2C19功能缺失等位基因为*2和*3。

临床怎么用

  • 对CYP2C19功能缺失等位基因非携带者且GA≤15.5%的小卒中或高危TIA患者,可考虑氯吡格雷联合阿司匹林治疗以降低卒中复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Dysglycemia may influence the predictive value of CYP2C19 loss-of-function allele for clinical efficacy of antiplatelet drug, but the role of glycated albumin (GA) remains unclear in patients with stroke on antiplatelet drugs. METHODS: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) included 2933 patients who had GA levels and CYP2C19 genotyping. Cox proportional hazards model was used to assess the interaction between CYP2C19 loss-of-function allele (*2, *3) carrier status and the effect of antiplatelet therapy based on their GA levels. RESULTS: There was significant interaction between carrier status and antiplatelet therapy regimen on the risk of recurrent stroke (P=0.03) in patients with GA levels of ≤15.5%, but not in those with GA levels of >15.5% (P=0.48). Only in noncarriers with low GA levels, dual-antiplatelet therapy reduced stroke recurrence (3.5%) compared with those on aspirin alone (14.7%; hazard ratio, 0.23; 95% confidence interval, 0.10-0.49; P<0.001). Similar effects were observed when examined the combined vascular event or ischemic stroke. No significant difference in bleeding was found among groups. CONCLUSIONS: In patients with minor stroke or high-risk transient ischemic attack, clopidogrel-aspirin when compared with aspirin alone reduced stroke recurrence only in noncarriers of CYP2C19 loss-of-function allele and normal GA levels. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lin Y, Wang A, Li J, et al. Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With CYP2C19 Genetic Variants. Stroke. 2017. PMID: 28289237. doi:10.1161/STROKEAHA.116.016463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。